ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Identity and Access Management (IAM) Architect at Recursion - ApplyBlast

Identity and Access Management (IAM) Architect

Recursion

22 days ago

3.4 on Glassdoor

Salt Lake City, Utah, United States

Hybrid

Full Time

Senior

4 applicants

View Job Listing

Apply to 100+ jobs

About this role

This role involves assessing and revamping the company's Identity and Access Management (IAM) strategy to support a zero-trust security framework across cloud and on-premise infrastructure. The position requires leading large-scale IAM projects, designing cloud-based identity governance solutions, and ensuring regulatory compliance for standards such as SOX and GxP. The successful candidate will act as a strategic advisor to cross-functional teams, integrating IAM principles into the broader security architecture while establishing key performance indicators for continuous improvement.

Responsibilities

Assess and revamp IAM strategy across products and infrastructure
Drive IAM implementation as part of zero-trust security strategy
Architect and design cloud-based identity governance solutions

Skills

Qualifications

Bachelor's degree in Computer ScienceMaster's degree in Information SecurityCISSPOSCPGWAPT

About Recursion

recursion.com

Headquarters

Salt Lake City, Utah, United States

Company Size

501-1000 employees

Founded

2013

View Profile

Recursion is a TechBio company that combines high-throughput experimental biology, automated imaging, and machine learning to decode biology and accelerate drug discovery. Its platform integrates large-scale biological datasets, AI models, and laboratory automation to identify and advance therapeutic candidates across multiple modalities and disease areas. Recursion develops an internal pipeline of programs and partners with biopharma and investors to translate discoveries into clinical-stage medicines. The company emphasizes a platform-first, scalable approach to make drug discovery faster, more reproducible, and more data-driven.